Subtype‐specific response to bevacizumab is reflected in the metabolome and transcriptome of breast cancer xenografts

Antiangiogenic therapy with bevacizumab has shown varying results in breast cancer clinical trials. Identifying robust biomarkers for selecting patients who may benefit from such treatment and for monitoring response is important for the future use of bevacizumab. Two established xenograft models re...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Mol Oncol
Main Authors: Borgan, Eldrid, Lindholm, Evita M., Moestue, Siver, Mælandsmo, Gunhild M., Lingjærde, Ole Christian, Gribbestad, Ingrid S., Børresen-Dale, Anne-Lise, Engebraaten, Olav, Sørlie, Therese
Formato: Artigo
Idioma:Inglês
Publicado: John Wiley and Sons Inc. 2012
Assuntos:
Papers
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5528408/
https://ncbi.nlm.nih.gov/pubmed/23142657
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.molonc.2012.10.005
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares